Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMED.L Regulatory News (MED)

  • There is currently no data for MED

AGM Statement

17 May 2018 07:00

RNS Number : 3520O
Medaphor Group PLC
17 May 2018
 

MedaPhor Group plc

("MedaPhor" or the "Group" or the "Company")

 

AGM Statement

 

 

 

MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, will hold its Annual General Meeting today at 10.30 a.m. at IP Group Offices, The Walbrook Building, 25 Walbrook, London, EC4N 8AF. At the meeting the Chairman, Riccardo Pigliucci, will make the following statement:

 

"The Group is trading in line with management's expectations, research and development work being undertaken by our Clinical Division is progressing well and Simulation Division sales in the UK and mainland Europe are showing good signs of recovery. Initial orders placed in our key territories for our recently launched BodyWorks point of care and emergency medicine simulator are also encouraging."

 

A copy of this announcement is available on the Group's website: www.medaphor.com

 

MedaPhor Group plc

www.medaphor.com

Stuart Gall, CEO

Ian Whittaker, COO

Tel: +44 (0)29 2075 6534

Cenkos Securities

Tel: +44 (0)20 7397 8900

Camilla Hume (Nominated Advisor)

Michael Johnson / Julian Morse (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001

 

 

 

 

 

 

 

 

 

 

 

About MedaPhor (www.investors.medaphor.com)

MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops artificial intelligence-based clinical image analysis software tools, augmented reality-based needle guidance software and advanced hi-fidelity haptic and manikin-based training simulators for medical practitioners.

Based in Cardiff and Oxford in the UK and Atlanta in the US and Hong Kong in Asia, MedaPhor operates two divisions:

Intelligent Ultrasound Simulation Division 

Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN and General Medical simulator training platform, the HeartWorks echocardiography simulator platform and the BodyWorks Eve Point of Care and Emergency Medicine Simulator. Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.

Intelligent Ultrasound Clinical Division

 Focuses on augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav and NeedleGuide. ScanNav uses machine-learning based algorithms to automatically identify, grade and capture good ultrasound images. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.

 

Some products in the pipeline may require US FDA approval, as such this material should be considered informational only and does not constitute an offer to sell or infer claims or benefits.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUNRURWSAVAUR
Date   Source Headline
14th Jan 201911:34 amRNSChange of Name
7th Jan 20197:00 amRNSTrading Update
14th Dec 20181:05 pmRNSHolding(s) in Company
13th Dec 20188:30 amRNSDirector/PDMR Shareholding
12th Dec 20181:24 pmRNSResults of General Meeting and Total Voting Rights
12th Dec 20187:00 amRNSResults of Open Offer
27th Nov 20183:35 pmRNSAI database exceeds 1 million images
26th Nov 20187:00 amRNSPlacing to raise £5.0m
23rd Nov 20183:56 pmRNSMedaPhor commences clinical trial for AnatomyGuide
13th Nov 20187:00 amRNSQuality control on ultrasound for HAPIN trial
9th Nov 20187:00 amRNSINTERGROWTH-21st Project the University of Oxford
10th Oct 20182:59 pmRNSHolding(s) in Company
9th Oct 20188:01 amRNSDirector/PDMR Shareholding
8th Oct 20187:00 amRNSPayment of deferred consideration
25th Jul 20187:00 amRNSHalf-year Report
23rd Jul 20187:00 amRNSMedaphor expands ScanNav AI pilot
7th Jun 20187:00 amRNSScanTrainer at Central Middlesex Hospital
30th May 20187:00 amRNSGrant of Options
29th May 20187:00 amRNSBodyWorks Eve installed at NYU School of Medicine
17th May 201810:54 amRNSResult of AGM
17th May 20187:00 amRNSAGM Statement
14th May 20187:00 amRNSScanNav AI software featured on ITV
24th Apr 20187:00 amRNSNotice of AGM
21st Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of Results
21st Feb 20187:00 amRNSOpening of Hong Kong office
19th Feb 20187:00 amRNSLaunch of new Point-of-Care Ultrasound simulator
12th Feb 20187:00 amRNSPilot of ultrasound AI software for pregnancy scan
7th Feb 20187:00 amRNSInvestor presentation
5th Feb 20187:00 amRNSInnovate UK grant award confirmed
3rd Jan 20187:00 amRNSTrading and IUL integration update
23rd Nov 20177:00 amRNSInnovate UK Grant Award
30th Oct 20173:19 pmRNSDirector Appointment
18th Oct 201712:46 pmRNSHolding(s) in Company
17th Oct 201711:05 amRNSSecond Price Monitoring Extn
17th Oct 201711:00 amRNSPrice Monitoring Extension
11th Oct 20178:17 amRNSHolding(s) in Company
10th Oct 20171:55 pmRNSHolding(s) in Company
9th Oct 20173:23 pmRNSHolding(s) in Company
9th Oct 20172:51 pmRNSHolding(s) in Company
6th Oct 20178:00 amRNSCompletion of Acquisition
5th Oct 201711:18 amRNSResult of General Meeting
21st Sep 20171:31 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSContract awarded at Mohawk College in Canada
19th Sep 20173:40 pmRNSAcquisition & Placing
17th Aug 20177:00 amRNSInstallation of 500th simulation system
10th Aug 20178:37 amRNSPayment of deferred consideration
31st Jul 20177:00 amRNSHalf-year Report
24th Jul 20177:00 amRNSMedaPhor wins first ScanTrainer customer in India
23rd May 201711:44 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.